New pill hopes to fight Hard-to-Treat cancers

NCT ID NCT05142592

Completed Disease control Sponsor: Nanjing Immunophage Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This early-phase trial tests an experimental oral drug called IPG7236 in people with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, then expanding to see if the drug can control tumor growth. About 196 participants will take the pill twice daily in 28-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPG7236 (oral tablet)
What this could lead to: If it works, this could point toward a new oral treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong: This is a very early, first-in-human trial with only 196 participants. The drug may not shrink tumors or could cause unexpected side effects. Success in early phases does not guarantee later approval.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PHARMACOKINETICS SAFETY ISSUES TOLERABILITY

Contacts and locations

Locations

NEXT Oncology

Austin, Texas, 12221, United States
Providence Portland Medical Center

Portland, Oregon, 97222, United States
Shandong Cancer Hospital

Jinan, Shangdong, China
Shanghai East Hospital

Shanghai, China
Shanghai General Hospital

Shanghai, China
Shanghai GoBroad Cancer Hospital China Pharmaceutical University

Shanghai, China
The First Affiliated Hospital Nanchang Univeristy

Nanchang, Jiangxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.